Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHEAD 3-45 Study (A3 and A45 Trials) of BAN2401 / lecanemab in preclinical Alzheimer's disease
jRCT2080225322Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Started Aug 2020; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080225322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225322.